Free Trial

Greenwich LifeSciences (GLSI) Competitors

Greenwich LifeSciences logo
$9.49 -0.23 (-2.37%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$9.74 +0.25 (+2.63%)
As of 10/17/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GLSI vs. BCYC, CTMX, RGNX, MNPR, PRTA, ETON, GOSS, CRVS, ARCT, and ESPR

Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Bicycle Therapeutics (BCYC), CytomX Therapeutics (CTMX), REGENXBIO (RGNX), Monopar Therapeutics (MNPR), Prothena (PRTA), Eton Pharmaceuticals (ETON), Gossamer Bio (GOSS), Corvus Pharmaceuticals (CRVS), Arcturus Therapeutics (ARCT), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry.

Greenwich LifeSciences vs. Its Competitors

Greenwich LifeSciences (NASDAQ:GLSI) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Greenwich LifeSciences presently has a consensus price target of $42.00, suggesting a potential upside of 342.57%. Bicycle Therapeutics has a consensus price target of $22.22, suggesting a potential upside of 172.00%. Given Greenwich LifeSciences' higher probable upside, research analysts clearly believe Greenwich LifeSciences is more favorable than Bicycle Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Greenwich LifeSciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Bicycle Therapeutics
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50

Greenwich LifeSciences has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Greenwich LifeSciences has higher earnings, but lower revenue than Bicycle Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Greenwich LifeSciencesN/AN/A-$15.79M-$1.36-6.98
Bicycle Therapeutics$35.28M16.05-$169.03M-$3.51-2.33

Greenwich LifeSciences has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -1,257.00%. Bicycle Therapeutics' return on equity of -32.43% beat Greenwich LifeSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Greenwich LifeSciencesN/A -700.90% -455.64%
Bicycle Therapeutics -1,257.00%-32.43%-26.80%

4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 51.7% of Greenwich LifeSciences shares are held by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Bicycle Therapeutics had 5 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 7 mentions for Bicycle Therapeutics and 2 mentions for Greenwich LifeSciences. Bicycle Therapeutics' average media sentiment score of 0.54 beat Greenwich LifeSciences' score of 0.30 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Greenwich LifeSciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bicycle Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Bicycle Therapeutics beats Greenwich LifeSciences on 9 of the 15 factors compared between the two stocks.

Get Greenwich LifeSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLSI vs. The Competition

MetricGreenwich LifeSciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$129.35M$3.44B$6.19B$10.55B
Dividend YieldN/A2.28%5.70%4.81%
P/E Ratio-6.9823.0185.5427.13
Price / SalesN/A481.55610.73132.72
Price / CashN/A46.9237.1060.81
Price / Book49.9510.4112.236.52
Net Income-$15.79M-$52.77M$3.33B$276.93M
7 Day Performance-10.89%2.31%1.17%1.93%
1 Month Performance-17.19%12.59%6.85%2.19%
1 Year Performance-29.86%11.18%58.93%34.62%

Greenwich LifeSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLSI
Greenwich LifeSciences
1.2141 of 5 stars
$9.49
-2.4%
$42.00
+342.6%
-29.9%$129.35MN/A-6.983Analyst Forecast
BCYC
Bicycle Therapeutics
3.5397 of 5 stars
$8.12
-2.4%
$22.22
+173.7%
-69.8%$576.63M$35.28M-2.31240News Coverage
Analyst Forecast
CTMX
CytomX Therapeutics
4.3156 of 5 stars
$3.40
+1.2%
$5.42
+59.3%
+171.2%$554.11M$138.10M6.07170
RGNX
REGENXBIO
4.4363 of 5 stars
$11.34
+3.8%
$28.38
+150.2%
+5.7%$551.61M$83.33M-3.30370Gap Down
MNPR
Monopar Therapeutics
3.193 of 5 stars
$102.05
+16.2%
$105.67
+3.5%
+1,356.9%$541.85MN/A-30.6510
PRTA
Prothena
2.3424 of 5 stars
$10.35
+3.0%
$20.50
+98.1%
-42.0%$540.99M$135.16M-1.84130Analyst Revision
ETON
Eton Pharmaceuticals
2.2468 of 5 stars
$18.08
-8.0%
$29.67
+64.1%
+117.7%$527.23M$39.01M-113.0020
GOSS
Gossamer Bio
3.3968 of 5 stars
$2.44
+7.0%
$8.50
+248.4%
+127.7%$518.43M$114.70M-3.94180
CRVS
Corvus Pharmaceuticals
2.2348 of 5 stars
$7.11
+2.6%
$13.75
+93.4%
-2.4%$516.38MN/A-7.0430News Coverage
Analyst Downgrade
ARCT
Arcturus Therapeutics
3.5903 of 5 stars
$19.39
+2.3%
$50.57
+160.8%
-2.3%$514.58M$152.31M-8.70180Positive News
ESPR
Esperion Therapeutics
3.6472 of 5 stars
$2.72
+7.5%
$7.00
+157.4%
+34.8%$510.11M$332.31M-5.55200

Related Companies and Tools


This page (NASDAQ:GLSI) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners